BioNano Genomics Inc vs VanEck Rare Earth/Strategic Metals — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while VanEck Rare Earth/Strategic Metals trades at $78.23. The key difference: VanEck Rare Earth/Strategic Metals is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | REMX | |
|---|---|---|
Market Cap | $13.20M | — |
Sector | Health | Sector/Thematic |
52-Week High | $4.92 | $109.53 |
52-Week Low | $1.09 | $47.36 |
Enterprise Value | $15.81M | — |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $76.27, down 4.38% today amid bearish technical signals. The ETF faces high volatility (~50% annualized) and significant China concentration risk, though recent news highlights growing institutional interest in rare earths as critical for AI and defense infrastructure. Technical indicators show oversold RSI readings but dominant bearish moving average signals.
Outlook remains speculative given geopolitical supply chain dependencies and commodity price sensitivity. Investment appeal hinges on long-term rare earth demand growth from technology and energy transitions, but risks include China export controls and ETF liquidity constraints. Current levels near support at $76 may attract tactical buyers despite near-term bearish momentum.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →